Clinical trial
A Phase 3, Multicenter, Prospective, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide (FA) Intravitreal 0.05 mg Insert (Yutiq 0.05 mg) in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
NCT05070728 is registered in ClinicalTrials.gov with EyePoint Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Prospective, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide (FA) Intravitreal 0.05 mg Insert (Yutiq 0.05 mg) in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- October 13, 2021
- Completion date
- April 12, 2023
- Enrollment
- 12 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.